Corporate ActionJun 3, 2026, 08:32 AM
Liminatus Pharma Raises $1.9M from Warrant Exercise, Issues New Warrants
AI Summary
Liminatus Pharma, Inc. announced it has entered into a warrant exercise agreement with existing accredited investors, resulting in the immediate exercise of 10,344,000 outstanding warrants for cash. The company raised $1.9 million in gross proceeds from this transaction. In consideration, Liminatus issued new unregistered warrants to purchase an aggregate of 20,688,000 shares of common stock, with an exercise price of $0.18 per share, contingent on stockholder approval.
Key Highlights
- Liminatus Pharma raised $1.9 million in gross proceeds from the warrant exercise.
- Existing warrants to purchase 10,344,000 shares of common stock were exercised.
- The exercise price of the existing warrants was reduced to $0.18 per share.
- New unregistered warrants to purchase 20,688,000 shares were issued to investors.
- The new warrants have an exercise price of $0.18 per share and require stockholder approval.
- Maxim Group LLC acted as warrant inducement agent and financial advisor for the transaction.
Price Impact
More from LIMN